Is HeartFlow Stock a Buy After Capricorn Investment Group Bought 1.7 Million Shares?

Capricorn Investment Group established a new position in HeartFlow (NASDAQ:HTFL), buying 1,661,601 shares in Q4 2025 worth an estimated $48.18M, representing 5.83% of its 13F reportable AUM. HeartFlow (market cap ~$2.22B) reported ~40% YoY revenue growth in 2025 ( ~$176M) but remains unprofitable (TTM net loss ~$125.4M); shares were $26.30 on March 20, 2026, down 10.7% YTD and well below a $41.22 52-week high. The trade brings HeartFlow into Capricorn’s portfolio but outside its top-five holdings, signaling selective institutional interest while likely having limited broader market impact.

Analysis

An institutional-sized allocation to an early-stage, AI-driven cardiac diagnostics platform materially raises the probability curve for faster commercial adoption—not because of share purchases per se, but because it signals conviction that hospitals will accept software-as-service economics for imaging workflows. Expect procurement timelines to compress from multi-year pilots to broader rollouts in winning health systems over 6–18 months if a handful of marquee contract wins appear, which would turn near-term revenue growth into durable ARR-like streams.

The more important second-order effect is competitive pressure on legacy imaging OEMs and FFR-CT challengers: incumbents face a choice between vertical integration (bundling analytics into scanners) or partnering/licensing. That decision will determine margin trajectories across the imaging supply chain and could bifurcate winners (those capturing software revenue) and losers (hardware-only vendors seeing rising price erosion and longer replacement cycles) over 12–36 months.

Primary risks are non-linear and idiosyncratic—payer coverage reversals, negative guideline updates, or slower-than-expected clinician workflow integration can wipe out expected ARR conversion and re-rate multiples quickly. Conversely, a single national payer positive decision or guideline inclusion is a binary catalyst that could rerate the name within 3–9 months and attract strategic M&A interest from larger healthcare tech acquirers.

Technically, low free float and limited public history mean episodes of outsized volatility around corporate updates; use that to establish positions slowly. From a thematic perspective, this is an AI monetization story that behaves more like recurring healthcare software than broad semiconductor-driven AI names, so correlate portfolio sizing and hedge structure accordingly rather than treating it as a pure AI beta trade.

Key Decisions for Investors

• Long HTFL with tail-protection: initiate a 1–2% portfolio position in HTFL (size to risk budget) and buy 9–12 month protective puts ~25% OTM to cap downside; target 50–75% upside in 9–18 months if adoption/coding catalysts materialize, expected payoff skewed positive vs 1:1 downside protection cost.
• Event-driven call spread: buy HTFL 3–6 month call spread (buy ATM, sell +40–60% OTM) ahead of expected payer/guideline/news windows to capture binary rerate with defined max loss equal to premium; aim for 3:1+ asymmetry if confirmed adoption news arrives.
• Relative-value pair: go long HTFL / short PL on equal notional for 6–12 months to isolate healthcare software monetization vs pure geospatial/data platform beta; trim pair if correlations break—this converts a directional bet into a thematic dispersion play with targeted 30–60% relative outperformance.
• Conviction LEAP for asymmetric upside: for investors/allocators with high risk tolerance, buy 18–24 month HTFL LEAP calls to capture takeover or guideline-driven rerating (target 2–4x return on positive adoption cascade) while keeping position <=0.5% portfolio to limit binary risk.